About
Syndeavor Therapeutics is developing a small molecule inhibitor of ACSS2 for the treatment of triple-negative breast cancer (TNBC) and non-small cell lung cancer (NSCLC).
Explore Syndeavor Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.